IDEXX Laboratories (NASDAQ:IDXX) and Atossa Genetics (NASDAQ:ATOS) Head-To-Head Analysis

Atossa Genetics (NASDAQ:ATOS) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Profitability

This table compares Atossa Genetics and IDEXX Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-49.42%	-44.76%
IDEXX Laboratories	24.65%	67.78%	31.08%

Risk and Volatility

Atossa Genetics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.

Institutional and Insider Ownership

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 7.6% of Atossa Genetics shares are owned by insiders. Comparatively, 1.0% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Atossa Genetics and IDEXX Laboratories, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2	0	2	1	2.40
IDEXX Laboratories	0	3	8	0	2.73

Atossa Genetics presently has a consensus target price of $6.33, indicating a potential upside of 766.27%. IDEXX Laboratories has a consensus target price of $763.50, indicating a potential upside of 9.02%. Given Atossa Genetics’ higher possible upside, analysts plainly believe Atossa Genetics is more favorable than IDEXX Laboratories.

Valuation & Earnings

This table compares Atossa Genetics and IDEXX Laboratories”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$25.50 million	($0.24)	-3.05
IDEXX Laboratories	$3.90 billion	14.35	$887.87 million	$12.61	55.54

IDEXX Laboratories has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

IDEXX Laboratories beats Atossa Genetics on 11 of the 14 factors compared between the two stocks.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.